9909
Herein , we describe 2 patients who developed unusual CD8 + cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab .
 adverse effect: CD8 + cutaneous lymphoproliferative disorders, efalizumab; adverse effect: CD8 + cutaneous lymphoproliferative disorders, infliximab
Given options, please tell me the relationships of all the listed entity pairs.Output format is "relation1: word1, word2; relation2: word3, word4". 
Option: adverse effect 
Text: {0} 
 Entity Pairs:  CD8 + cutaneous lymphoproliferative disorders, efalizumab; CD8 + cutaneous lymphoproliferative disorders, infliximab 
Answer:
 adverse effect: CD8 + cutaneous lymphoproliferative disorders, efalizumab; adverse effect: CD8 + cutaneous lymphoproliferative disorders, infliximab